PFNX - Pfenex Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
8.75
-0.83 (-8.66%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close9.58
Open0.00
Bid0.00 x 800
Ask0.00 x 1800
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume180,130
Market Cap276.479M
Beta (3Y Monthly)0.69
PE Ratio (TTM)N/A
EPS (TTM)-0.92
Earnings DateNov 5, 2019 - Nov 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.00
Trade prices are not sourced from all markets
  • GlobeNewswire

    Pfenex to Present at the Cantor Healthcare Conference

    SAN DIEGO, Sept. 16, 2019 -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression.

  • GlobeNewswire

    Pfenex to Participate in the Oppenheimer Fall Summit

    SAN DIEGO, Sept. 10, 2019 -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression.

  • GlobeNewswire

    Pfenex Earns $11 Million Development Milestone under its Development and License Agreement with Jazz Pharmaceuticals

    Pfenex Inc. (NYSE American: PFNX) today announced that it has earned an $11 million development milestone under its development and license agreement with Jazz Pharmaceuticals. The milestone is associated with process development activities for PF745, a recombinant crisantaspase with half-life extension technology. “We are very pleased with our progress on PF745 and we believe the Jazz collaboration overall further validates the versatility of our proprietary protein expression platform and the quality of our development capabilities,” said Eef Schimmelpennink, Chief Executive Officer of Pfenex.

  • GlobeNewswire

    Pfenex Appoints Dr. Steve Kay to Scientific Advisory Board

    Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to improve protein therapies for unmet patient needs, today announced the appointment of Steve Kay, Ph.D., to the Pfenex Scientific Advisory Board. “Dr. Kay is a highly regarded biologist that brings a wealth of research experience to our Scientific Advisory Board and will complement the existing board in support of the Pfenex scientific strategy. Steve joins several other respected scientists and physicians we have recently appointed to executive and advisory roles in the company to support our evolving R&D strategy with a goal of further leveraging the Pfēnex Expression Technology platform to expand our development pipeline,” said Eef Schimmelpennink, Chief Executive Officer of Pfenex.

  • Thomson Reuters StreetEvents

    Edited Transcript of PFNX earnings conference call or presentation 8-Aug-19 8:30pm GMT

    Q2 2019 Pfenex Inc Earnings Call

  • Pfenex (PFNX) Reports Q2 Loss, Misses Revenue Estimates
    Zacks

    Pfenex (PFNX) Reports Q2 Loss, Misses Revenue Estimates

    Pfenex (PFNX) delivered earnings and revenue surprises of 4.00% and -50.25%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Pfenex Announces Appointment of New Board Member, Lorianne Masuoka, M.D.

    Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to improve protein therapies for unmet patient needs, today announced the appointment of Lorianne Masuoka, MD to its Board of Directors, effective immediately. “We are pleased to welcome Dr. Masuoka to the Pfenex Board of Directors.

  • GlobeNewswire

    Pfenex Reports Second Quarter 2019 Results and Provides Business Update

    Pfenex Inc. (NYSE American: PFNX) is a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to develop and improve protein therapies for unmet patient needs. Today Pfenex Inc. reported financial results for the second quarter ended June 30, 2019 and provided a business update.

  • Will Pfenex (PFNX) Report Negative Earnings Next Week? What You Should Know
    Zacks

    Will Pfenex (PFNX) Report Negative Earnings Next Week? What You Should Know

    Pfenex (PFNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    Pfenex and Arcellx Announce a Development, Evaluation and License Agreement

    First Arcellx sparX protein successfully completed process development using Pfēnex Expression Technology® platform Second sparX program initiated by Arcellx SAN DIEGO, Aug..

  • GlobeNewswire

    Pfenex to Announce Second Quarter 2019 Financial Results on August 8

    SAN DIEGO, July 25, 2019 -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression.

  • Those Who Purchased Pfenex (NYSEMKT:PFNX) Shares Three Years Ago Have A 23% Loss To Show For It
    Simply Wall St.

    Those Who Purchased Pfenex (NYSEMKT:PFNX) Shares Three Years Ago Have A 23% Loss To Show For It

    As an investor its worth striving to ensure your overall portfolio beats the market average. But the risk of stock...

  • Hedge Funds Have Never Been This Bullish On Pfenex Inc (PFNX)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Pfenex Inc (PFNX)

    World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients' money after undertaking a rigorous examination of any potential stock. They are particularly successful in this regard when it comes to small-cap stocks, which their peerless research gives them a big information advantage on when it comes to judging their worth. […]

  • Pfenex Sees Hammer Chart Pattern: Time to Buy?
    Zacks

    Pfenex Sees Hammer Chart Pattern: Time to Buy?

    Pfenex has been struggling lately, but the selling pressure may be coming to an end soon.

  • GlobeNewswire

    Pfenex to Participate at the JMP Securities Life Sciences Conference

    SAN DIEGO, June 05, 2019 -- Pfenex Inc. (NYSE American: PFNX) a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression.

  • GlobeNewswire

    Pfenex and Alvogen Announce European Medicines Agency Accepts Marketing Authorization Application for PF708

    Pfenex Inc. (NYSE American: PFNX) and Alvogen today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) submitted by our partner Alvogen for PF708 (teriparatide).  The product is proposed as a therapeutic equivalent in the treatment of osteoporosis to Forteo®. The product is filed with the EMA as a biosimilar in the treatment of osteoporosis to Forsteo®, which achieved $289 million sales in the E.U. and $1.6 billion in global product sales in 2018.

  • Pfenex Inc. (PFNX) Shares March Higher, Can It Continue?
    Zacks

    Pfenex Inc. (PFNX) Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in Pfenex Inc. (PFNX).

  • Pfenex (PFNX) Reports Q1 Loss, Tops Revenue Estimates
    Zacks

    Pfenex (PFNX) Reports Q1 Loss, Tops Revenue Estimates

    Pfenex (PFNX) delivered earnings and revenue surprises of 52.00% and 84.05%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Pfenex Reports First Quarter 2019 Results and Provides Business Update

    SAN DIEGO, May 09, 2019 -- Pfenex Inc. (NYSE American: PFNX) is a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression.

  • Pfenex (PFNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
    Zacks

    Pfenex (PFNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    Pfenex (PFNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    Pfenex to Announce First Quarter 2019 Financial Results on May 9

    SAN DIEGO, April 25, 2019 -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression.

  • GlobeNewswire

    Pfenex Appoints Dr. Robert Peach to Scientific Advisory Board

    Pfenex Inc. (NYSE American: PFNX), today announced the appointment of Robert Peach, Ph.D. to the Pfenex Scientific Advisory Board. “We are very excited to have Dr. Peach join our Scientific Advisory Board and look forward to his insight and contributions as we leverage our Pfēnex Expression Technology platform to expand our development pipeline,” said Eef Schimmelpennink, Chief Executive Officer of Pfenex. “I am looking forward to working with the innovative team at Pfenex and the rest of the Scientific Advisory Board on their efforts to expand their development pipeline leveraging the Pfēnex Expression Technology platform.

  • GlobeNewswire

    Pfenex Announces Successful Expiration of 45 Day Waiting Period Under Hatch-Waxman Act

    Pfenex Inc. (NYSE American: PFNX) a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to improve protein therapies for unmet patient needs, today announced the expiration of the 45-day period for Eli Lilly & Co. (“Lilly”) to file a lawsuit under the Hatch-Waxman Act and stay the approval of PF708 for 30 months. In addition, Pfenex is developing hematology/oncology products, including PF743, a recombinant crisantaspase, and PF745, a recombinant crisantaspase with half-life extension technology, in collaboration with Jazz Pharmaceuticals.

  • GlobeNewswire

    Pfenex to Participate at the William Blair Late-Stage Therapeutics Conference

    SAN DIEGO, March 27, 2019 -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression.